.png){kind=icon}
返回
K
Kathleen N. Moore
university of nebraska medical center
84H指数
1.1K论文数
4.7W被引数
收录论文 148
发表时间
.png){kind=icon}
Associations between molecular classification and response to intrauterine levonorgestrel therapy in patients with medically managed endometrial cancer and endometrial intraepithelial neoplasia: a multicenter Endometrial Cancer Molecularly Targeted Therapy (ECMT2) Consortium study分子分型与接受宫内左炔诺孕酮治疗的患者中子宫内膜癌和子宫内膜上皮内瘤变的治疗反应之间的关联：一项多中心子宫内膜癌分子靶向治疗(ECMT2)联盟研究.png)
PREAI
.png){kind=icon}
分享.png){kind=icon}
收藏Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovaryI期可行性试验：评估紫杉醇/卡铂联合Galunisertib（一种抑制1型TGF-B受体激酶域的小分子抑制剂）在初诊、持续性或复发性子宫或卵巢癌肉瘤患者中的疗效。.png)
Gynecologic Oncology
Gynecologic OncologyIF3.7
PREAI
分享收藏Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancermirvetuximab soravtansine（一种靶向叶酸受体α（FRα）的抗体偶联药物，ADC）与pembrolizumab联合治疗铂耐药性卵巢癌患者的安全性与有效性gynecologic oncology
gynecologic oncologyIF4.1
PREAI
分享收藏Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial在预后不良的卵巢癌中，添加免疫检查点抑制剂atezolizumab到一线化疗对无进展生存期的影响：IMagyn050试验的一项回顾性分析gynecologic oncology
OAAI
gynecologic oncologyIF4.1
OAAI分享收藏